TITLE:
Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type
AUTHORS:
Amen Hamdy Zaky, Ahmed Refaat Abd Elzaher, Ola Nabih
KEYWORDS:
Lung Cancer, Maintenance Chemotherapy, Vinorelbine, EGFR-Wild Type
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.10 No.12,
December
10,
2019
ABSTRACT:
Background: This study was performed to evaluate the efficacy
and safety of switch maintenance therapy with oral vinorelbine in advanced
non-small cell lung cancer (NSCLC) with adenocarcinoma limited to epidermal
growth factor receptor (EGFR) wild type. Materials
and Methods: In this single randomized
trial, patients with advanced stage (IIIB and IV) NSCLC with adenocarcinoma
EGFR wild-type status, treated with 6 cycles of platinum based chemotherapy.
Patients did not show progression after first-line chemotherapy were randomly
assigned to receive switch maintenance with vinorelbine (80 mg/m2,
day 1, 8) (group I) or the best supportive care until disease progression
(group II). Results: The median progression free survival (PFS) was 9.7
months for group I versus 5.7 months for group II with statistically
significant difference between both groups [HR = 1.15; 95% CI 1.19 to 1.49; P
value = 0.002], while the median overall survival (OS) was 13.2 months for
group I versus 11.9 months for group II with no statistically significant
differences between both groups [HR = 1.24; 95% CI 1.05 to 1.46; P value = 0.
3]. The patients who received oral vinorelbine had tolerable toxicity profile. Conclusion: Switch maintenance therapy with oral vinorelbine,
though improve PFS, did not improve OS in patients with NSCLC with
adenocarcinoma EGFR wild type.